{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hyperkalemia&page=2",
    "query": {
      "condition": "Hyperkalemia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hyperkalemia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T07:46:23.762Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01349218",
      "title": "Relationship Between Potassium Level in Venous Blood Samples Drawn and Heel Sticks In Infants and Newborns",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hyperkalemia"
      ],
      "interventions": [
        {
          "name": "Blood sample drawn from a vein",
          "type": "OTHER"
        },
        {
          "name": "Blood sample drawn from a heel stick",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "6 Months",
        "sex": "ALL",
        "summary": "Up to 6 Months"
      },
      "enrollment_count": 31,
      "start_date": "2014-03",
      "completion_date": "2014-03",
      "has_results": false,
      "last_update_posted_date": "2016-05-13",
      "last_synced_at": "2026-05-22T07:46:23.762Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01349218"
    },
    {
      "nct_id": "NCT04676646",
      "title": "Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hyperkalaemia",
        "Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Sodium zirconium cyclosilicate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 366,
      "start_date": "2021-03-08",
      "completion_date": "2024-07-15",
      "has_results": true,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-05-22T07:46:23.762Z",
      "location_count": 12,
      "location_summary": "Fairhope, Alabama • Los Angeles, California • Torrance, California + 9 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Hazel Crest",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04676646"
    },
    {
      "nct_id": "NCT04585542",
      "title": "Comparison of Potassium Binders in the ER",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Hyperkalemia",
        "Oral Potassium Binders"
      ],
      "interventions": [
        {
          "name": "Polyethylene Glycol 3350",
          "type": "DRUG"
        },
        {
          "name": "Sodium Polystyrene Sulfonate Oral Suspension [SPS]",
          "type": "DRUG"
        },
        {
          "name": "Patiromer",
          "type": "DRUG"
        },
        {
          "name": "Sodium zirconium cyclosilicate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2020-10-20",
      "completion_date": "2025-01-31",
      "has_results": true,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-05-22T07:46:23.762Z",
      "location_count": 1,
      "location_summary": "Orange, California",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04585542"
    },
    {
      "nct_id": "NCT00498537",
      "title": "Spironolactone for Reducing Proteinuria in Diabetic Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 30,
      "start_date": "2003-01",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2008-10-17",
      "last_synced_at": "2026-05-22T07:46:23.762Z",
      "location_count": 1,
      "location_summary": "Dayton, Ohio",
      "locations": [
        {
          "city": "Dayton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00498537"
    },
    {
      "nct_id": "NCT05056727",
      "title": "A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Insufficiency, Chronic",
        "Hyperkalemia"
      ],
      "interventions": [
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Lisinopril",
          "type": "DRUG"
        },
        {
          "name": "Valsartan",
          "type": "DRUG"
        },
        {
          "name": "Irbesartan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 1112,
      "start_date": "2021-09-30",
      "completion_date": "2024-02-07",
      "has_results": true,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-05-22T07:46:23.762Z",
      "location_count": 42,
      "location_summary": "Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more",
      "locations": [
        {
          "city": "Surprise",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canyon Country",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05056727"
    },
    {
      "nct_id": "NCT03071263",
      "title": "Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperkalemia",
        "Resistant Hypertension"
      ],
      "interventions": [
        {
          "name": "Patiromer",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Spironolactone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Relypsa, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 295,
      "start_date": "2017-01-23",
      "completion_date": "2018-11-27",
      "has_results": true,
      "last_update_posted_date": "2021-05-12",
      "last_synced_at": "2026-05-22T07:46:23.762Z",
      "location_count": 3,
      "location_summary": "Hollywood, Florida • Miami Lakes, Florida • Chicago, Illinois",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03071263"
    },
    {
      "nct_id": "NCT03813407",
      "title": "An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperkalaemia"
      ],
      "interventions": [
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level",
          "type": "DRUG"
        },
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)",
          "type": "DRUG"
        },
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)",
          "type": "DRUG"
        },
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)",
          "type": "DRUG"
        },
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": 140,
      "start_date": "2019-04-02",
      "completion_date": "2030-02-21",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-05-22T07:46:23.762Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03813407"
    },
    {
      "nct_id": "NCT06763549",
      "title": "COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cardiopulmonary Failure",
        "Myocardial Infarction (MI)",
        "Heart Decompensation",
        "Heart Failure",
        "HFrEF - Heart Failure with Reduced Ejection Fraction",
        "HFpEF - Heart Failure with Preserved Ejection Fraction",
        "Syncopation",
        "Syncope",
        "Ischemic Cardiovascular Disease",
        "STEMI",
        "STEMI (ST Elevation MI)",
        "Atrial Fibrillation (AF)",
        "Atrial Enlargement",
        "LVF",
        "Conduction Defect",
        "Conduction Abnormalities",
        "Heart Block",
        "Valvular Diseases",
        "Cardiac Output, Low",
        "Stroke Volume",
        "Stroke Volume Variation",
        "Hyperkalemia",
        "Hypercalcemia",
        "Hypocalcemia",
        "LV Dysfunction",
        "QT Prolongation",
        "Sudden Cardiac Death Due to Cardiac Arrhythmia",
        "Ventricular Arrhythmia",
        "Pacing",
        "Pacing Induced Dyssynchrony",
        "Silent Ischemia",
        "Pericarditis",
        "Sleep Related Breathing Disorder",
        "RSA",
        "Apnea, Obstructive",
        "Cardiac Output Measurement",
        "Respiratory Impedance",
        "CRT And/or ICD",
        "Infarction",
        "Cardiomyopathies, Primary",
        "Hypertrophy"
      ],
      "interventions": [
        {
          "name": "SUBPROTOCOL A",
          "type": "DEVICE"
        },
        {
          "name": "SUBPROTOCOL B",
          "type": "DEVICE"
        },
        {
          "name": "SUBPROTOCOL C",
          "type": "DEVICE"
        },
        {
          "name": "SUBPROTOCOL D",
          "type": "DEVICE"
        },
        {
          "name": "SUBPROTOCOL E",
          "type": "DEVICE"
        },
        {
          "name": "SUBPROTOCOL F",
          "type": "DEVICE"
        },
        {
          "name": "SUBPROTOCOL G",
          "type": "DEVICE"
        },
        {
          "name": "SUBPROTOCOL H",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Peerbridge Health, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15000,
      "start_date": "2024-11-16",
      "completion_date": "2026-04-15",
      "has_results": false,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-05-22T07:46:23.762Z",
      "location_count": 1,
      "location_summary": "Melbourne, Florida",
      "locations": [
        {
          "city": "Melbourne",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06763549"
    },
    {
      "nct_id": "NCT00290160",
      "title": "Early Protein Supplementation on Prevention of Hyperkalemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hyperkalemia"
      ],
      "interventions": [
        {
          "name": "Protein supplementation",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "1 Minute",
        "maximum_age": "12 Hours",
        "sex": "ALL",
        "summary": "1 Minute to 12 Hours"
      },
      "enrollment_count": 62,
      "start_date": "2002-12",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-05-22T07:46:23.762Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00290160"
    },
    {
      "nct_id": "NCT04847232",
      "title": "Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperkalemia"
      ],
      "interventions": [
        {
          "name": "Sodium Zirconium Cyclosilicate (SZC)",
          "type": "DRUG"
        },
        {
          "name": "SZC Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 2690,
      "start_date": "2021-04-30",
      "completion_date": "2024-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-06-18",
      "last_synced_at": "2026-05-22T07:46:23.762Z",
      "location_count": 57,
      "location_summary": "Huntsville, Alabama • Mesa, Arizona • Bakersfield, California + 47 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Granada Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04847232"
    }
  ]
}